A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Myasthenia Gravis Panel 3 : 10211
Test CodeACRABT or 10211
Alias/See Also
Acetylcholine Receptor Binding Antibody, Acetylcholine Receptor Blocking Antibody, Acetylcholine Receptor Modulating Antibody, Striated Muscle Antibody
CPT Codes
86041, 86042, 86043, 86255
Includes
Acetylcholine Receptor Binding Antibody, Acetylcholine Receptor Blocking Antibody, Acetylcholine Receptor Modulating Antibody, Striated Muscle Antibody with Reflex to Titer
If Striated Muscle Antibody Screen is positive, then Striated Muscle Antibody Titer will be performed at an additional charge (CPT code: 86256)
If Striated Muscle Antibody Screen is positive, then Striated Muscle Antibody Titer will be performed at an additional charge (CPT code: 86256)
Instructions
Serum separator tube.
Transport Container
Centrifuge serum separator tube and transport, 2 mL serum (Min: 0.8 mL).
Transport Temperature
Refrigerated.
Specimen Stability
Room temperature: 4 days; Refrigerated: 14 days; Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis; Grossly lipemic; Microbially contaminated
Methodology
Radioimmunoassay, Radiobinding Assay, Immunofluorescence Assay
Setup Schedule
Monday & Thursday
Report Available
2-6 days (From receipt at performing laboratory)
Limitations
Acetylcholine Receptor Modulating Antibody & Striated Muscle Antibody Screen: This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Reference Range
Acetylcholine Receptor Binding Antibody:
Negative ≤0.30 nmol/L
Equivocal 0.31-0.49 nmol/L
Positive ≥0.50 nmol/L
Acetylcholine Receptor Blocking Antibody:
<15 % Inhibition
Acetylcholine Receptor Modulating Antibody:
<32 % Inhibition
Striated Muscle Antibody:
Negative
Negative ≤0.30 nmol/L
Equivocal 0.31-0.49 nmol/L
Positive ≥0.50 nmol/L
Acetylcholine Receptor Blocking Antibody:
<15 % Inhibition
Acetylcholine Receptor Modulating Antibody:
<32 % Inhibition
Striated Muscle Antibody:
Negative
Clinical Significance
Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody. There is a strong correlation between the presence of striated muscle antibody and the presence of thymoma.
Performing Laboratory
Quest Diagnostics